NCT05905328View on ClinicalTrials.gov

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Cytokine Release Syndrome
Interventions
DRUG

CTO1681 10 μg

Administered 3 times daily for 15 days (initial cohort).

DRUG

CTO1681 20 μg

Administered 3 times daily for 15 days (successive cohort).

DRUG

CTO1681 30 μg

Administered 3 times daily for 15 days (successive cohort).

Trial Locations (6)

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

27705

RECRUITING

Duke Cancer Institute, Durham

30912

RECRUITING

Georgia Cancer Center at Augusta University, Augusta

92868

RECRUITING

University of California, Irvine - Chao Family Comprehensive Cancer Center, Orange

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

CytoAgents, Inc.
All Listed Sponsors
lead

CytoAgents, Inc.

INDUSTRY